Brief: Xeris Biopharma Reports Fourth Quarter And Full-Year 2022 Financial Results

Xeris Biopharma Holdings

08/03/2023 12:46

March 8 (Reuters) - Xeris Biopharma Holdings Inc
 XERS.O :
    * XERIS BIOPHARMA REPORTS FOURTH QUARTER AND FULL-YEAR 2022
FINANCIAL RESULTS AND PROVIDES 2023 FINANCIAL GUIDANCE
    * Q4 EARNINGS PER SHARE VIEW $-0.16, REVENUE VIEW $31.0
MILLION --
REFINITIV IBES DATA
    * ENDED 2022 WITH $122.0M IN CASH, CASH EQUIVALENTS, AND
SHORT-TERM INVESTMENTS
    * SEES 2023 TOTAL REVENUES OF $135 MILLION -$165M MILLION
    * SEES 2023 YEAR-END CASH, CASH EQUIVALENTS, AND SHORT-TERM
INVESTMENTS OF $45 MILLION -$65MLN
    * FY2023 REVENUE VIEW $152.3 MILLION -- REFINITIV IBES DATA

Source text for Eikon:  ID:nBw9zSTf4a 
Further company coverage:  XERS.O 

 ((Reuters.Briefs@thomsonreuters.com;))